Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

British Journal of Ophthalmology

Volumn 97, Issue 8, 2013, Pages 1032-1035

  Cho, Hyung ^a   Shah, Chirag P ^a   Weber, Marissa ^a   Heier, JeffreyS ^a  

^a Ophthalmic Consultants of Boston ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL SUBFOVEAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; EXUDATIVE RETINA MACULA AGE RELATED DEGENERATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

DRUGS; MACULA; NEOVASCULARISATION; RETINA; TREATMENT MEDICAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETREATMENT; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84880005310     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303344     Document Type: Article

References (28)

1. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
2. Brown DM, Michels M, Kaiser PK, et al . Ranibizumab versus verteporforin photodynamic therapy for neovascular age-related macular degeneration. Two year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e5.
3. Brown DM, Kaiser PK, Michels M, et al . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
4. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
7. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
8. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8. (Pubitemid 34920936)
9. Heier JS, Boyer D, Nguen QD, et al. CLEAR-IT 2 Investigators. The 1 year results of CLEAR-IT 2, a phase 2 study of vascular endothelial Trap-Eye dosed as needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-106.
10. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8. (Pubitemid 351684178)
11. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;1897-908.
12. Holladay JT. Proper method for calculating average visual acuity. J Refractive Surgery 1997;13:388-91. (Pubitemid 27369067)
13. Hau V. VEGF Trap-Eye (Afl ibercept) Effectiveness in Wet AMD Patients Recalcitrant to Ranibizumab and Bevacizumab. American Society of Retina Specialists Annual Meeting; 27 August 2012, Las Vegas, NV.
14. Williams P. The initial response to aflibercept for neovascular AMD with persistent fluid on OCT (non-responders). American Society of Retina Specialists Annual Meeting; 27 August 2012, Las Vegas, NV.
15. Barbazetto I. Aflibercept for patients previously treated with anti-VEGF therapy for age-related macular degeneration. American Society of Retina Specialists Annual Meeting; 27 August 2012, Las Vegas, NV.
16. Sharma A. Resolution of persistent macular edema, SRF and/or RPE detachment after single injection of aflibercept in patients with neovascular AMD. American Society of Retina Specialists Annual Meeting; 27 August 2012, Las Vegas, NV.
17. Wheatley H. Intravitreal aflibercept in eyes with active Choroidal Neovascularization (CNV) secondary to AMD after multiple ranibizumab or bevacizumab injections. American Society of Retina Specialists Annual Meeting; 27 August 2012, Las Vegas, NV.
18. Packo K. Initial experience with aflibercept in the management of patients with persistent exudation due to AMD undergoing chronic ranibizumab therapy. American Society of Retina Specialists Annual Meeting; 27 August 2012, Las Vegas, NV.
19. Major J. Pigment epithelial detachment improvement in non-naive neovascular AMD patients after intravitreal aflibercept. 27 August 2012. American Society of Retina Specialists Annual Meeting, Las Vegas, NV.
20. Busbee BG, Murahashi WY, Li Z, et al. Efficacy and safety of 2.0 mg or 0.5 mg ranibizumab in patients with subfoveal neovascular AMD: HARBOR study. Program and Abstracts of the American Academy of Ophthalmology 2011 Annual Meeting; 22-25 October 2011; Orlando, Florida. Session PA031.
21. Brown DM, Chen E, Mariani A, et al. Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013;120:349-54.
22. Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Goodman LS, Hardman JG, Limbird LE, et al. eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th edn. New York: McGraw-Hill, 2001:115-54.
23. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularization. Br J Ophthalmol 2012;96:14-20.
24. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:3115-20.
25. Schaal S, Kaplan JG, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008;115:2199-205.
26. Double-masked study of efficacy and safety of IVT VEGF Trap-eye in subjects with wet AMD (VIEW 1) [clinical trials.Gov identifier: NCT00509795] ClinicalTrials.gov [online]. http//clinicaltrials.gov/ct2/show/NCT00509795
27. VEGF Trap-eye: investigation of efficacy and safety in wet AMD (VIEW 2). [ClinicalTrials.gov identifier: NCT00637377] ClinicalTrials.gov [online]. http//clinicaltrials.gov/ct2/show/NCT00637377
28. Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.